Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Posted By Global Banking and Finance Review

Posted on January 16, 2025

Novartis loses emergency bid to block Entresto generic in US

By Blake Brittain

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday.

The U.S. Court of Appeals for the District of Columbia Circuit halted the launch, which could have begun as early as Thursday, while it considers Novartis' emergency request for a longer pause.

A separate ruling on Wednesday from U.S. District Judge Dabney Friedrich in Washington had cleared a hurdle for MSN to introduce the first U.S. generic of Switzerland-based Novartis' best-selling drug, which brought the company more than $6 billion in revenue in 2023.

An attorney for MSN declined to comment on the decisions. An attorney and spokespeople for Novartis did not immediately respond to requests for comment.

MSN's version of Entresto was approved by the U.S. Food and Drug Administration last year.

Novartis sued MSN and others seeking to launch Entresto generics for patent infringement. The U.S. Court of Appeals for the Federal Circuit last week reversed a 2023 decision by a Delaware judge that invalidated one of the patents.

Novartis argued in a court filing that the appeals court ruling maintained the company's exclusive rights to sell Entresto until July. The company said MSN was preparing to launch its generic on Thursday, when Novartis' patent expires and MSN said that the ban would end.

The Federal Circuit on Tuesday rejected Novartis' request for a mandate that would immediately block the generic.

Novartis separately sued the U.S. Food and Drug Administration in Washington federal court on Monday to block the launch. Friedrich said she would reject Novartis' request during a hearing late on Wednesday.

(Reporting by Blake Brittain in Washington; Editing by David Bario, Stephen Coates and Jamie Freed)

Recommended for you

  • Trump says he may meet Ukraine's Zelenskiy next week

  • Trump says Nippon Steel will invest in US Steel, not buy it

  • Airbus postpones development of new hydrogen aircraft